C2N is at the Gerontological Society of America (GSA) 2024 Annual Scientific Meeting from Nov. 13-16. Please stop by to see us at booth 200 to learn about the Precivity? tests. They’re innovative blood tests intended for use in patients 55 and older with signs or symptoms of mild cognitive impairment or dementia. These tests aid healthcare providers in the detection of amyloid plaques in the brain, a pathological hallmark of Alzheimer's disease, and inform medical management and treatment decisions. C2N Scientific Advisor Mark Monane, MD, MBA, will be presenting at these sessions: Friday, Nov. 15 from Noon-1:30 p.m. PT: Implementation Study of the Use of a Blood Biomarker Test in Alzheimer’s Disease: Clinician Survey from QUIP II Study Friday, Nov. 15 at 2 p.m. PT: Poster session, Clinical Utility Data of a Multi-Analyte Blood Biomarker Test for Evaluating Cognitive Impairment Saturday, Nov. 16 from 5:30-7:00 p.m. PT: Early Clinical Utility Data of a Multi-Analyte Blood Biomarker Test for Evaluating Cognitive Impairment #GSA2024 #aging #Alzheimersdiagnostics #bloodtests #bloodbiomarkers #GSA #GSA24
C2N Diagnostics
生物技术研究
St Louis，Missouri 7,027 位关注者
Fierce Medtech named C2N one of its Fierce 15 for 2020; "one of the most promising private companies in the industry.”
关于我们
C?N Diagnostics’ vision is to bring Clarity Through Innovation?. It focuses its therapeutic discovery efforts around mechanism-based approaches to prevent or stop the progression of human neurological disorders. Diagnostic efforts revolve around bringing accurate, widely accessible, and cost-effective blood tests to the clinic for the betterment of patient care and brain health monitoring. Its lead commercial product, the PrecivityAD? blood test, is a mass spectrometry-based test performed in C?N’s CLIA-certified lab that measures in blood multiple analytes including Aβ42, Aβ40, and apolipoprotein E isoforms. While the test by itself cannot diagnose Alzheimer’s disease — which is a clinical diagnosis made by a health care provider — the test is an important new tool for physicians to aid in the evaluation process. PrecivityAD?, which can only be ordered through a health care provider, predicts brain amyloid plaques as determined by PET scan results and in 2019 it received a Breakthrough Device Designation from the U.S. Food and Drug Administration. The PrecivityAD? blood test also has achieved the CE Mark from the European Union. For more information visit www.C2N.com.
- 网站
-
https://www.c2ndiagnostics.com/
C2N Diagnostics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- St Louis，Missouri
- 类型
- 私人持股
- 创立
- 2007
地点
-
主要
获取路线
20 S Sarah St
US，Missouri，St Louis，63108
C2N Diagnostics员工
动态
-
Medscape reports on how healthcare providers are using blood biomarkers to help diagnose Alzheimer’s disease. Prominently mentioned in the coverage is C2N Diagnostics’ PrecivityAD2. The story includes details about the study published in the Journal of the American Medical Association that showed the PrecivityAD2 test delivered a highly statistically significant accuracy of over 90% at a pre-defined, single binary cutoff compared to cerebrospinal fluid (CSF) analysis or amyloid PET analysis. https://lnkd.in/gaBJjvxZ #Medscape #bloodbiomarkers #Alzheimersdisease #healthcareproviders #precisionmedicine #bloodtests #healthnews
-
Joel Braunstein, MD, CEO of C2N, spoke at today’s Alzheimer's Drug Discovery Foundation Fall Luncheon Research Symposium in New York on the transformative power of biomarkers to aid clinicians in making an early and accurate diagnosis of Alzheimer’s disease for patients with cognitive impairment. Moderated by Mark Roithmayr, the discussion also included comments from esteemed co-panelists Howard Fillit, MD, Danielle Graham, PhD, and Russ Lebovitz, MD, PhD, about innovations in precision neurological care. The panel also answered pressing questions from the audience. Dr. Howard Fillit of ADDF called blood biomarkers for Alzheimer’s disease “revolutionary” for patient management. Congratulations to ADDF on another highly informative symposium focused on the significant advances being achieved in Alzheimer’s disease.???#ADDF #AlzheimersDrugDiscoveryFoundation #cognitiveimpairment #precisionmedicine #bloodbiomarkers #Alzheimers #Alzheimersdisease
-
-
C2N Diagnostics has a non-exclusive agreement with Mayo Clinic Laboratories for inclusion of the Precivity? tests in Mayo Clinic Laboratories’ test offerings to its clients. Click to read how meeting the needs of patients is the cornerstone of test development at both Mayo Clinic Laboratories and C2N Diagnostics. https://lnkd.in/escRMiDF #MayoClinicLaboratories #Alzheimersdisease #precisionmedicine #bloodbiomarkertests
Diagnostic ecosystem boosts access to timely Alzheimer's disease testing - Insights
news.mayocliniclabs.com
-
We’re getting ready for the 2024 NAMCP Medical Directors Institute Fall Managed Care Forum from Nov. 7-8. This is a terrific opportunity for C2N to share details about the Precivity? tests, which are innovative new blood tests intended for use in patients 55 and older with signs or symptoms of mild cognitive impairment or dementia. These tests aid healthcare providers in the detection of amyloid plaques in the brain, a pathological hallmark of Alzheimer's disease, and inform medical management and treatment decisions. The Managed Care Forums are a joint creation of the American Association of Integrated Healthcare Delivery Systems (AAIHDS), the American Association of Managed Care Nurses (AAMCN) and the NAMCP Medical Directors Institute. https://lnkd.in/d2EM8SK #NAMCP #bloodtests #managedcare #precisionmedicine #Alzherimersdisease #dementia #FallManagedCareForum
-
-
At C2N, our team members are proud to go the extra mile to help in the race against Alzheimer’s disease — and they take that comment literally! Our colleague Brianne Peters took part in the New York City Marathon this weekend. Brianne chose to join the Alzheimer's Association? team and help raise funds for a great cause while training for the race. She was one of the top individual fundraising participants for the Alzheimer’s Association team. Thank you Brianne for your support of individuals living with cognitive impairment. #alzheimersassociation #nycmarathon #alzheimers #biomarkers #Alzheimersdiagnostics
-
-
The Washington Post health reporter Laurie McGinley recently answered online questions about the progress occurring in diagnosing and treating Alzheimer’s disease. Click to read her initial reporting on research involving the C2N’s Precivity? line of blood tests that help healthcare providers diagnose Alzheimer’s disease; the research found the PrecivityAD2 test delivered a highly statistically significant accuracy of over 90% at a pre-defined, single binary cutoff compared to cerebrospinal fluid (CSF) analysis or amyloid PET analysis. https://archive.ph/QkSaI Click to read her answer discussing the accuracy of blood tests to aid in Alzheimer’s disease diagnosis (scroll to question 10). https://archive.ph/xLjQ6 #WashingtonPost #Alzheimers #Alzheimersdisease #precisiomedicine #bloodtests
-
Dr. Sheena Aurora, Vice President of Neurology of #C2N Diagnostics, presents at today’s CTAD Late Breaking Roundtable on Plasma p-tau217 assays in clinical practice: Current uses and future considerations for diagnosing Alzheimer’s disease. #CTAD #ClinicalTrialsforAlzheimersDisease #CTAD2024
-
-
Joel Braunstein, MD, CEO of #C2N Diagnostics, presents ground-breaking clinical utility data on the PrecivityAD2? test in his CTAD session titled “An evaluation of the impact of a multi-analyte blood biomarker test for evaluating cognitive impairment: Results of the QUIP II clinical utility study. (Publication in review.) #CTAD #ClinicalTrialsforAlzheimersDisease #CTAD2024
-
-
See our graphics and calendar below for details about C2N-related sessions on Friday, November 1 at CTAD: 9:00 a.m. – 9:15 a.m. CEST LB22: Timing of changes in Alzheimer’s disease plasma biomarkers using amyloid and tau PET clocks Poster session: Friday, November 1 – 7:15 a.m. – 5:00 p.m. CEST P199 Sequential Administration of Digital Testing to Screen For Cognitive Impairment Followed By Blood Based Biomarkers To Assist With Timely Detection And Accurate Diagnosis of Alzheimer’s Disease in AdventHealth ? P200 Clinical Management during the Davos Alzheimer’s Collaborative Early Detection of Cognitive Impairment Program in Six Countries #CTAD #ClinicalTrialsforAlzheimersDisease #CTAD2024
-